Venous thromboembolism in Shizuoka Observational Study

Venous thromboembolism in Shizuoka Observational Study - VISUAL Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015243

Enrollment

1000

Registered

2014-09-24

Start date

2014-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with metastatic or locally advanced solid tumor 2) Patients will receive chemotherapy during 4 weeks 3) Aged 20 or more 4) Performance status (ECOG) of 0-2 5) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients cannnot receive an iodinated contrast 2) Congenital coagulation factor deficiencies 3) Venous thromboembolism diagnosed 4 weeks before enrollment 4) Receivng anticoagulant 5) Patients cannnot receive venous ultrasound 6) Pregnant or lactating women or women of childbearing potential 7) Psychiatric disease

Design outcomes

Primary

Measure	Time frame
The incidence of venous thromboembolism for 24 weeks	—

Secondary

Measure	Time frame
The incidence of venous thromboembolism for 24 weeks by primary cancer site, The incidence of venous thromboembolism (at enrollment, 12 week, 24 week), the incidence of symptomatic venous thromboembolism for 24 weeks, The incidence of pulmonary thromboembolism, treatment of venous thromboembolism	—

Countries

Japan

Contacts

Public ContactHirotsugu Kenmotsu

Shizuoka Cancer Center Devision of Thoracic Oncology

h.kenmotsu@scchr.jp055-989-5222

Outcome results